Design Therapeutics, Inc. (DSGN)
15.11
-0.14
(-0.92%)
USD |
NASDAQ |
Aug 28, 16:00
15.09
-0.02
(-0.13%)
After-Hours: 20:00
Design Therapeutics Max Drawdown (5Y) : 95.20% for July 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| July 31, 2026 | 95.20% |
| June 30, 2026 | 95.20% |
| May 31, 2026 | 95.20% |
| April 30, 2026 | 95.20% |
| March 31, 2026 | 95.20% |
| February 28, 2026 | 95.20% |
| January 31, 2026 | 95.20% |
| December 31, 2025 | 95.20% |
| Date | Value |
|---|---|
| November 30, 2025 | 95.20% |
| October 31, 2025 | 95.20% |
| September 30, 2025 | 95.20% |
| August 31, 2025 | 95.20% |
| July 31, 2025 | 95.20% |
| June 30, 2025 | 95.20% |
| May 31, 2025 | 95.20% |
| April 30, 2025 | 95.20% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Amgen, Inc. | 24.86% |
| AnaptysBio, Inc. | 85.45% |
| 4D Molecular Therapeutics, Inc. | 95.23% |
| Inhibrx Biosciences, Inc. | -- |
| Agenus, Inc. | 98.84% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -23.30 |
| Beta (5Y) | 1.626 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 77.92% |
| Historical Sharpe Ratio (5Y) | -0.107 |
| Historical Sortino (5Y) | -0.1667 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 32.23% |